CY1120950T1 - Θεραπεια ινωσης - Google Patents

Θεραπεια ινωσης

Info

Publication number
CY1120950T1
CY1120950T1 CY181101130T CY181101130T CY1120950T1 CY 1120950 T1 CY1120950 T1 CY 1120950T1 CY 181101130 T CY181101130 T CY 181101130T CY 181101130 T CY181101130 T CY 181101130T CY 1120950 T1 CY1120950 T1 CY 1120950T1
Authority
CY
Cyprus
Prior art keywords
fiber treatment
treatment
fibrosis
interleukin
relief
Prior art date
Application number
CY181101130T
Other languages
English (en)
Inventor
Stuart Alexander Cook
Sebastian Schaefer
Original Assignee
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55274842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120950(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Singapore Health Serv Pte Ltd filed Critical Singapore Health Serv Pte Ltd
Publication of CY1120950T1 publication Critical patent/CY1120950T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Αποκαλύπτεται η θεραπεία, πρόληψη ή ανακούφιση ίνωσης σε ένα υποκείμενο μέσω της χορήγησης ενός παράγοντα παρεμπόδισης της δράσης Ιντερλευκίνης 11 (IL-11).
CY181101130T 2015-12-16 2018-10-31 Θεραπεια ινωσης CY1120950T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1522186.4A GB201522186D0 (en) 2015-12-16 2015-12-16 Treatment of fibrosis
PCT/EP2016/081430 WO2017103108A1 (en) 2015-12-16 2016-12-16 Treatment of fibrosis

Publications (1)

Publication Number Publication Date
CY1120950T1 true CY1120950T1 (el) 2019-12-11

Family

ID=55274842

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101130T CY1120950T1 (el) 2015-12-16 2018-10-31 Θεραπεια ινωσης

Country Status (24)

Country Link
US (15) US10035852B2 (el)
EP (7) EP3431499A1 (el)
JP (2) JP6753933B2 (el)
KR (1) KR20180097645A (el)
CN (2) CN116036284A (el)
AU (7) AU2016369407B2 (el)
CA (1) CA3007750A1 (el)
CY (1) CY1120950T1 (el)
DK (1) DK3298040T3 (el)
ES (1) ES2692773T3 (el)
GB (1) GB201522186D0 (el)
HK (1) HK1254287A1 (el)
HR (1) HRP20181692T1 (el)
HU (1) HUE041433T2 (el)
LT (1) LT3298040T (el)
NZ (1) NZ744307A (el)
PL (1) PL3298040T3 (el)
PT (1) PT3298040T (el)
RS (1) RS57894B1 (el)
SG (2) SG11201804836RA (el)
SI (1) SI3298040T1 (el)
TR (1) TR201815415T4 (el)
WO (1) WO2017103108A1 (el)
ZA (1) ZA201803727B (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
GB201621439D0 (en) * 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
WO2018109174A2 (en) 2016-12-16 2018-06-21 Singapore Health Services Pte Ltd Il-11 antibodies
GB201716733D0 (en) * 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
GB201806918D0 (en) * 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
CA3126322A1 (en) 2019-01-21 2020-07-30 Singapore Health Services Pte. Ltd. Treatment of hepatotoxicity
GB201902419D0 (en) * 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
GB201906291D0 (en) 2019-05-03 2019-06-19 Singapore Health Serv Pte Ltd Treatment and prevention of metabolic diseases
MX2021013356A (es) 2019-05-03 2022-03-11 Singapore Health Serv Pte Ltd Tratamiento y prevencion de enfermedades metabolicas.
JP2022545344A (ja) * 2019-08-05 2022-10-27 ノボキュア ゲーエムベーハー Ｉｌ１１活性を阻害することによって、腫瘍治療電場（ｔｔフィールド）に対するがん細胞の感受性を高める
KR102270700B1 (ko) * 2019-11-01 2021-06-30 한국과학기술연구원 폐 섬유증의 예방 또는 치료를 위한 올리고뉴클레오티드 중합체와 생체 적합성 양이온성 펩타이드로 이루어지는 폐 특이적 약물 전달체 및 이의 이용
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
CN113651888B (zh) * 2020-08-13 2022-08-16 广东东阳光药业有限公司 Il-11的抗体及其应用
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
CN117157317A (zh) 2021-02-26 2023-12-01 拜耳公司 用于治疗异常子宫出血的IL-11或IL-11Ra的抑制剂
EP4376948A1 (en) 2021-07-26 2024-06-05 Boehringer Ingelheim International GmbH Treatment and prevention of alcoholic liver disease
WO2023111196A1 (en) 2021-12-16 2023-06-22 Singapore Health Services Pte. Ltd. Treatment and prevention of glomerular disease
CN115414346B (zh) * 2022-08-29 2023-09-29 湖南复瑞生物医药技术有限责任公司 一种应用胺碘酮构造肺纤维化模型的方法
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475096A (en) 1990-06-11 1995-12-12 University Research Corporation Nucleic acid ligands
DE69535274T2 (de) 1994-12-22 2007-06-06 Genetics Institute, LLC, Cambridge Verwendung eines menschlichen interleukin-11 rezeptors
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6126933A (en) 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US5679339A (en) 1995-06-27 1997-10-21 Keith; James Method of using IL-11 for treating spondyloarthropies
US6540993B1 (en) 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US6649192B2 (en) 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
GB9702944D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
GB9721961D0 (en) 1997-10-16 1997-12-17 Glaxo Group Ltd Novel molecules
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
US6953777B2 (en) 1999-03-11 2005-10-11 Genetics Indtitute LLC Use of interleukin-11 to prevent immune-mediated cytotoxicity
AU5756100A (en) * 1999-06-21 2001-01-09 Genetics Institute Inc. Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB0021668D0 (en) 2000-09-04 2000-10-18 Smithkline Beecham Plc New use
AU2002362088A1 (en) 2001-12-06 2003-06-23 Catholic University Method and composition for inducing weight loss
MXPA05002899A (es) 2002-09-16 2005-05-27 Wyeth Corp Formulaciones de liberacion controlada para administracion oral de un agente terapeutico polipeptido y sus metodos de uso.
JP2007537716A (ja) 2003-12-16 2007-12-27 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼイション サイトカイン結合ドメイン
EP1720562A4 (en) 2004-01-15 2009-10-28 Scios Inc METHOD FOR TREATING CARDIAL REMODELING AFTER MYOCARDIAL DAMAGE
WO2005098041A2 (en) 2004-03-26 2005-10-20 University Of Florida Research Foundation, Inc. Detection and treatment of fibrotic disorders
ES2309427T3 (es) 2004-08-27 2008-12-16 Conaris Research Institute Ag Secuencias de nucleotidos optimizidas que codifican para sgp130.
WO2007067602A1 (en) 2005-12-06 2007-06-14 Wyeth Interleukin-11 compositions and methods of use
NZ574028A (en) 2006-07-05 2010-10-29 Fibrotech Therapeutics Pty Ltd Tranilast analogues (substituted cinnamoyl anthranilate compounds) for treatment of conditions associated with firbrosis
US8361966B2 (en) * 2006-10-27 2013-01-29 Osaka University Use of interleukin-11 as therapeutic agent for heart disease
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
US7993637B2 (en) 2007-10-26 2011-08-09 Csl Limited IL-11 muteins
US8182814B2 (en) 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
US8518888B2 (en) 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
KR101133769B1 (ko) 2011-04-18 2012-04-09 한국생명공학연구원 신규한 옥사졸리딘계 및 인돌계 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물
JP6545105B2 (ja) 2013-02-07 2019-07-17 シーエスエル、リミテッド Ｉｌ−１１ｒ結合タンパク質及びその使用
CN105497893B (zh) 2015-12-10 2019-02-01 黑龙江省科学院高技术研究院 IL-11单克隆抗体在抑制PI3K/Akt信号通路中的应用
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
RU2016125115A (ru) 2016-06-23 2017-12-28 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов
WO2018109174A2 (en) 2016-12-16 2018-06-21 Singapore Health Services Pte Ltd Il-11 antibodies
GB201621431D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore The Decoy cytokine receptor
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
RU2016151730A (ru) 2016-12-28 2018-06-29 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Антитела для лабораторной диагностики концентрации интерлейкина-11
GB201716733D0 (en) 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
NL2020093B1 (en) 2017-12-15 2019-06-25 Stahl Int B V Process for producing aqueous polyurethane dispersions in a continuous manner; apparatus suitable for performing such a process; and products obtained by said process
GB201806918D0 (en) 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies

Also Published As

Publication number Publication date
HRP20181692T1 (hr) 2018-12-14
NZ744307A (en) 2019-03-29
US10927169B2 (en) 2021-02-23
US20170174759A1 (en) 2017-06-22
WO2017103108A1 (en) 2017-06-22
JP7102474B2 (ja) 2022-07-19
US10870696B2 (en) 2020-12-22
KR20180097645A (ko) 2018-08-31
US20190002553A1 (en) 2019-01-03
AU2018229487A1 (en) 2018-10-04
US20210188962A1 (en) 2021-06-24
US20180371078A1 (en) 2018-12-27
US10822405B2 (en) 2020-11-03
AU2018229484B9 (en) 2019-09-12
EP3298040B1 (en) 2018-08-01
US10894825B2 (en) 2021-01-19
AU2018229485B2 (en) 2019-08-08
PL3298040T3 (pl) 2019-07-31
US20180362639A1 (en) 2018-12-20
US20180362638A1 (en) 2018-12-20
AU2016369407A1 (en) 2018-08-02
CN108495861A (zh) 2018-09-04
GB201522186D0 (en) 2016-01-27
CA3007750A1 (en) 2017-06-22
AU2016369407B2 (en) 2018-09-13
EP3428187A1 (en) 2019-01-16
US20180362640A1 (en) 2018-12-20
AU2018229484A1 (en) 2018-10-04
DK3298040T3 (en) 2018-11-05
EP3428186A1 (en) 2019-01-16
SG10201908380TA (en) 2019-11-28
US20180362634A1 (en) 2018-12-20
AU2018229483A1 (en) 2018-10-04
LT3298040T (lt) 2018-12-10
US20180362641A1 (en) 2018-12-20
AU2018229487B2 (en) 2019-08-08
ZA201803727B (en) 2019-03-27
EP3428188A1 (en) 2019-01-16
JP2020189879A (ja) 2020-11-26
US20180371077A1 (en) 2018-12-27
US10106603B2 (en) 2018-10-23
HUE041433T2 (hu) 2019-05-28
EP3431498A1 (en) 2019-01-23
PT3298040T (pt) 2018-11-13
AU2018229482A1 (en) 2018-10-04
EP3298040A1 (en) 2018-03-28
US10894827B2 (en) 2021-01-19
EP3431500A1 (en) 2019-01-23
TR201815415T4 (tr) 2018-11-21
SI3298040T1 (sl) 2019-01-31
CN108495861B (zh) 2023-01-10
AU2018229486A1 (en) 2018-10-04
US20180362635A1 (en) 2018-12-20
US20180362633A1 (en) 2018-12-20
AU2018229485A1 (en) 2018-10-04
RS57894B1 (sr) 2019-01-31
US10865240B2 (en) 2020-12-15
EP3431499A1 (en) 2019-01-23
US11939374B2 (en) 2024-03-26
JP6753933B2 (ja) 2020-09-09
US20180265579A1 (en) 2018-09-20
AU2018229482B2 (en) 2019-08-08
JP2019502689A (ja) 2019-01-31
ES2692773T3 (es) 2018-12-05
US10899832B2 (en) 2021-01-26
US10889642B2 (en) 2021-01-12
US10870697B2 (en) 2020-12-22
AU2018229486B2 (en) 2019-08-08
US20180362637A1 (en) 2018-12-20
US10865239B2 (en) 2020-12-15
US10865241B2 (en) 2020-12-15
US10894826B2 (en) 2021-01-19
AU2018229483B2 (en) 2019-08-08
HK1254287A1 (zh) 2019-07-19
US20180362636A1 (en) 2018-12-20
US10035852B2 (en) 2018-07-31
CN116036284A (zh) 2023-05-02
SG11201804836RA (en) 2018-07-30
AU2018229484B2 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
CY1120950T1 (el) Θεραπεια ινωσης
CY1123833T1 (el) Μεθοδοι προληψης καρδιαγγειακων συμβαντων σε δυσλιπιδαιμικους πληθυσμους υπολειπομενου κινδυνου
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
CY1121826T1 (el) Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
MX2019005401A (es) Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma.
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2019008546A (es) Usos terapeuticos de un polvo de insectos.
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
CY1121566T1 (el) Νευροπροστατευτικο και ενδειξη αυτου
BR112019005539A2 (pt) métodos de tratamento de lesão renal aguda
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
PH12018502318A1 (en) Compositions and methods for treatment of inflammation of infection of the eye
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
CY1122374T1 (el) Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
MX2017009313A (es) Formulaciones intravenosas de baclofeno y metodos de tratamiento.
EA202092045A1 (ru) Лечение и предупреждение преэклампсии
MX2017016533A (es) Metodo para tratar glomeruloesclerosis focal y segmentaria primaria.
CY1122769T1 (el) Αγωγη της περιφερικης νευροπαθειας των μικρων ινων
EA202190219A1 (ru) Лечение и предупреждение повреждения из-за воздействия радиационного излучения